Tiziano Barbui

Research interests

Publications

• International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

  Blood · 2022 · https://doi.org/10.1182/blood.2022015850

• Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

  Leukemia · 2018 · https://doi.org/10.1038/s41375-018-0077-1

• The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion

  Blood Cancer Journal · 2018 · https://doi.org/10.1038/s41408-018-0054-y

• MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.76.4886

• Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

  Leukemia · 2016 · https://doi.org/10.1038/leu.2016.148

• Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

  Leukemia · 2015 · https://doi.org/10.1038/leu.2015.233

• Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

  Blood · 2014 · https://doi.org/10.1182/blood-2014-05-579136

• Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

  Leukemia · 2013 · https://doi.org/10.1038/leu.2013.163

• Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

  Blood · 2013 · https://doi.org/10.1182/blood-2013-03-488098

• Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)

  Blood · 2012 · https://doi.org/10.1182/blood-2012-07-444067

• JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1110556

• Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2012.42.3863

• Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1208500

• Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.31.8436

• Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.34.5298

• Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

  Blood · 2009 · https://doi.org/10.1182/blood-2008-11-185132

• Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome

  Transplantation and Cellular Therapy · 2009 · https://doi.org/10.1016/j.bbmt.2009.08.024

• Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

  Blood · 2009 · https://doi.org/10.1182/blood-2009-04-216044

• Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

  Blood · 2008 · https://doi.org/10.1182/blood-2008-01-135897

• Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

  Haematologica · 2008 · https://doi.org/10.3324/haematol.12053

• Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

  Blood · 2007 · https://doi.org/10.1182/blood-2006-12-064287

• JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis

  Blood · 2007 · https://doi.org/10.1182/blood-2007-07-099184

• Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

  Blood · 2007 · https://doi.org/10.1182/blood-2007-04-083501

• Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.07.062

• A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

  Journal of Thrombosis and Haemostasis · 2005 · https://doi.org/10.1111/j.1538-7836.2005.01340.x

• Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera

  New England Journal of Medicine · 2004 · https://doi.org/10.1056/nejmoa035572

• Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature

  Blood · 2003 · https://doi.org/10.1182/blood-2002-02-0441

• A multicenter study of treatment of primary CNS lymphoma

  Neurology · 2002 · https://doi.org/10.1212/wnl.58.10.1513

• Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.

  PubMed · 2000

• The Threshold for Prophylactic Platelet Transfusions in Adults with Acute Myeloid Leukemia

  New England Journal of Medicine · 1997 · https://doi.org/10.1056/nejm199712253372602

• Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.

  PubMed · 1997 · https://doi.org/10.1182/blood.v90.3.1014

• Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis

  New England Journal of Medicine · 1995 · https://doi.org/10.1056/nejm199504273321704

• Lupus Anticoagulant IgG's (LA) Are Not Directed to Phospholipids only, but to a Complex of Lipid-Bound Human Prothrombin

  Thrombosis and Haemostasis · 1991 · https://doi.org/10.1055/s-0038-1646476

• Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor

  The Lancet · 1990 · https://doi.org/10.1016/0140-6736(90)91374-j

• Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.

  Journal of Clinical Oncology · 1990 · https://doi.org/10.1200/jco.1990.8.3.556

Current projects

No projects listed.